Kornimate/medical-research-clean huggingface dataset:
decision-making processes while online grocery shopping

Conditions: Nutrition Poor

Summary: individuals living with food insecurity are disproportionately affected by overweight and obesity and associated chronic health problems. there remains a lack of sustainable and scalable interventions targeting widespread barriers to access to healthy foods in this population to increase the nutritional quality of foods purchased for preparation and consumption at home. this randomized controlled proof-of-principle trial was designed to examine the feasibility and initial efficacy of a "default option" in enhancing the nutritional quality of groceries selected via the online shopping service of a local grocery store under conditions that mimic the financial constraints typical of individuals living with food insecurity. in behavioral economics, the "default option" refers to the option a consumer selects if no active choice is made. the notion of the default option is based on the concept of "asymmetrical" or "libertarian paternalism," which seeks to subtly shift consumer behavior in a manner that promotes welfare, but without overtly interfering with the individual's freedom to choose. it was hypothesized that the "default" option effectively increases the nutritional quality of foods purchased online, compared to monetary incentives and psychoeducation about nutrition. female undergraduate students (n = 60) selected food for one week using the online shopping service of a local grocery store with a budget corresponding to maximum weekly supplemental nutrition assistance program (snap) benefits. before completing the task again, participants were randomized to: (1) a small monetary "incentive" for selecting groceries that meet nutritional guidelines (n = 17), (2) an "educational" brochure (n = 24), or (3) a "default" pre-filled online shopping cart containing a nutritionally balanced selection of groceries to which they could freely make changes (n = 18). primary outcome measures capture the nutritional quality of groceries selected/ purchased.


Eligibility criteria:
inclusion criteria: * age 18 or older * fluent in written and spoken english * able to provide informed consent exclusion criteria: * significant dietary restrictions (i.e., meat avoidance, food allergies, religious dietary restrictions, etc.) * likely presence of current eating disorder diagnosis (score \>/= 2 on scoff screening measure)

Keywords: proof-of-principle feasibility
emergency department (ed) self-monitoring pilot covid-19

Conditions: COVID; Covid-19; SARS-CoV 2

Summary: this feasibility study is being conducted to understand how discharged emergency department patients who were tested for the sars-cov-2 virus (covid-19) engage with a symptom-tracking web application. study participants that are enrolled in the study will be asked to enter daily information about their health into the covidx web application (app.). in addition, patients will answer questions regarding anxiety levels, use a pulse oximeter to record information (if you own one or are given one). the investigators predict that participants will be able to engage with the covidx web application over several days to weeks for the purposes of symptom tracking, and may have decreased anxiety over the study period.


Eligibility criteria:
inclusion criteria: * reported symptoms of viral illness during ed encounter * tested for sars-cov-2 (covid-19) during ed encounter * discharged home from the emergency department exclusion criteria: * prisoners * residents of congregate living facilities who are already being monitored * baseline oxygen requirement * patients whose primary goals of care are palliative * pregnant women

Keywords: coronavirus
effect of anti-inflammatory (itis) diet in rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Osteoarthritis

Summary: to study the effect of anti-inflammatory diet on clinical and biological outcomes in rheumatoid arthritis

the investigators would like to evaluate how inflammation occurs in the joints of subjects with arthritis, and identify molecules and bacteria that can predict whether a rheumatic subject will flare. blood, urine and stool will be evaluated in the laboratory and compared to their own samples after changes in diet. this is an exploratory study, which is meant to gather preliminary data about the quick effects of changes in diet and treatment on molecules in blood/urine and bacteria in stools. these studies can provide clues to the cause of disease and might ultimately lead to new therapies.

Eligibility criteria:
inclusion criteria: * patients diagnosed of rheumatoid arthritis * without changes in treatment in the last 3 months exclusion criteria: * food allergies * pregnancy
validation of mms test for cancer monitoring

Conditions: Colo-rectal Cancer; Stomach Cancer; Melanoma; Sarcoma

Summary: the purpose of this study is the validation of mms test to detect active tumor growth in different cancer types before and after therapy, as well as in the course of therapy and for subsequent relapse control compared to standard methods (clinical examination, imaging, tumor markers). it should be consider whether the mms test has comparable diagnostic accuracy, and thus can replace more expensive or invasive procedures in future.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of colo-rectal cancer * clinical diagnosis of stomach cancer * suspected diagnosis of melanoma exclusion criteria: * colitis ulcerosa * morbus crohn * cancer in time period two years before * cancer therapy in time period two years before

Keywords: colo-rectal cancer stomach cancer melanoma mms test therapy monitoring sarcoma
a biomarker-driven therapeutic strategy for esophageal cancer chemoradiotherapy in patients with resectable adenocarcinoma of the esophagus and esophagogastric junction

Conditions: Esophageal Cancer

Summary: preoperative chemoradiotherapy followed by surgery has been accepted as the standard of care for resectable adenocarcinoma of the esophagus and esophagogastric junction (egj). however, in a large part of the cases the tumor is extremely resistant to chemoradiotherapy, and those patients do not benefit from this treatment but are exposed to its negative consequences such as toxicity and delayed surgical therapy. the hypothesis is that a biomarker-driven therapeutic strategy in which patients will receive preoperative chemoradiotherapy or upfront surgery based on the basal tumor expression of birc3 could improve the r0 resection rate if compared with a standard strategy in unselected patients.

borges trial is a multicenter, randomized phase ii study of birc3-expression directed preoperative chemoradiotherapy in patients with resectable adenocarcinoma of the esophagus and egj. the main objective of this proposal is to provide evidence for a novel therapeutic strategy with enormous significance for patients affected by this disease. only a part of the patients with esophageal adenocarcinoma benefit from neoadjuvant therapy, and the clinical efficacy of chemoradiotherapy is reduced by the pre-existence of cellular drug resistance. thus, there is an urgent need to identify patients who could not benefit from preoperative treatment. the study will define an innovative therapeutic strategy directed by the expression of birc3 as a predictive marker for discriminating patients who will most likely be resistant to preoperative chemoradiotherapy.

Eligibility criteria:
inclusion criteria: * histologically proven adenocarcinoma of the esophagus and egj (siewert i/ii) surgical resectable (ct2-4a, n0-1, m0), as determined by endoscopic ultra sound (eus) and or pet-tc scan. ct1n1 tumors are eligible, t1n0 tumors and in situ carcinoma are not eligible. * if tumor extends below the egj junction into the proximal stomach, the bulk of the tumor must involve the esophagus or ge junction. the tumor must not extend more than 2 cm into the stomach (siewert iii). gastric cancers with minor involvement of the ge junction or esophagus are not eligible. * age \>18, no age upper limit unless patient would be unable to tolerate chemoradiotherapy. * have given written informed consent prior to any study-specific procedures. * ecog performance status 0-2. * no prior thoracic radiotherapy allowed. * adequate hematological, renal, cardiac, hepatic and pulmonary functions. exclusion criteria: -

Keywords: esophageal-gastric junction cancer, preoperative chemoradiotherapy, birc3
optimising hip mobility, hamstring flexibility and performance using lightback

Conditions: Injury;Sports

Summary: in athletics, in the sprint and hurdles disciplines, muscle injuries account for a significant proportion of injuries. the hamstrings are particularly vulnerable, accounting for between 12% and 26% of all injuries in these sports. a single-blind study was conducted on 20 hurdler patients with the intention of assessing hip mobility, hamstring flexibility and performance. to collect this data, the research team will conduct examinations and interviews with the athletes in two groups: an experimental group using lightback and a placebo group.


Eligibility criteria:
inclusion criteria: * sprinters and hurdlers aged 18 to 30 years. * no history of recent (less than 6 months) hamstring or hip injury. * signed informed consent. exclusion criteria: * cruciate or hamstring tears less than 6 months old; * hip and back surgery less than 3 months old; * chronic or acute back problems; * pregnancy; * osteoporosis * tumours, bone cancer of the hip and pelvis; * direct trauma to the back of the thigh less than 6 months old. * orthopaedic or neurological pathologies affecting mobility or muscle activation. * participation in another specific training protocol

Keywords: range of motion prevention physiotherapy athletics
xeloda vs monitoring in advanced colorectal cancer responsive to chemotherapy

Conditions: Colorectal Cancer

Summary: to compare maintenance chemotherapy with xeloda to control after best response with first line chemotherapy in advanced colorectal cancer. main endpoint is progression free survival. a total of 300 patients will be included.


Eligibility criteria:
inclusion criteria: * patients with metastatic colorectal cancer (confirmed histologically) with objective response or stabilization after at least 6 cycles of first line chemotherapy (treatment of choice is selected freely by the investigator according to the recommendations and consensus in force), * the interval between completion of first line chemotherapy and randomization should not exceed 4 weeks * age\>18 years * ecog status 0 to 2 * biological criteria prior to any chemotherapy: neutrophils\>1.5 109 g/l, platelets\>100 109/l, haemoglobin\>10 g/dl, creatininaemia\<150 mol/l, bilirubinaemia\<2x normal level * signed informed consent * life expectancy \> 3 months exclusion criteria: * metastatic colorectal cancer treated with more than one modality of first line chemotherapy (including oral fluoropyrimidines) * tumour progression after first line chemotherapy or before randomization * other tumour pathology * symptomatic cerebral metastases * any severe uncontrolled disease in addition to colorectal cancer (in particular decompensated cardiac failure (lvef\<50%) or coronary insufficiency) * lack of integrity of the upper gi tract: malabsorption syndrome or major surgery of the stomach or the small intestine * severe renal impairment (creatinine clearance \< 30 ml/min) * severe psychiatric disorder (other than controlled depressive syndrome) * patient participating in another experiment * pregnant women
comparative study of diagnostic and prognosis biomarkers of prostate cancer in liquid biopsy

Conditions: Prostate Cancer; Healthy Donors

Summary: constitution of a biological collection within the framework of the establishment of a diagnostic, prognostic and active surveillance test for prostate cancer from long non-coding rna biomarkers, in 3 cohorts of patients, with cancer of the prostate, with suspected cancer without biopsy confirmation or with prostatic hyperplasia and healthy donors. this biological collection will also be used as a support for further researches on the identification of biomarkers and genetic markers to improve the prognosis and diagnostic management of patients with prostate pathologies.

multicenter, riph 2 study, evaluating on 3 patient cohorts the feasibility of setting up a diagnostic test, prognosis and active surveillance of prostate cancer using long non-coding rna biomarkers. for patients agreeing to participate in the study and having signed a consent form, during their routine care consultation in the urology department, will have a blood sample and a urine sample after prostate massage as part of the study, and if necessary, a tissue sample as part of the treatment. patients with prostate cancer will be followed as part of their care at least annually, and their follow-up data will be collected as part of the study, without additional sampling. a blood sample and a urine sample after prostate massage will be carried out during a single consultation at the cic henri mondor for

Eligibility criteria:
inclusion criteria: concerning patients: 1. / patient with suspected prostate cancer or prostatic hyperplasia with a psa level ≥ 4 ng / ml 2. / patient diagnosed by prostate mri in the course of treatment 3. / no infectious episode in the week before the visit (in particular no urinary tract infection) documented by dipstick and absence of fever 4. / information of the patient and signature of informed consent or his legal representative. 5. / participant affiliated to a social security scheme regarding healthy volunteers: 1. / male from 50 to 70 years old 2. / psa level \< 4 ng / ml 3. / no infectious episode in the week before the visit (in particular no urinary tract infection), documented by dipstick and the absence of fever 4. / absence of cancer and history of haematological pathologies \< 5 years (in particular leukemia, lymphoma). 5. / patient information and signature of consent exclusion criteria: 1 / participants who refused to participate in the biological collection 2) persons deprived of their liberty or under guardianship. 3) inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.

Keywords: diagnostic prognosis prostate cancer long non-coding rna biomarkers
the smokefree app smoking cessation study

Conditions: Smoking Cessation; Smoking; Smoking Reduction; Smoking Habit

Summary: smokefree is a theory-driven and evidence-based stop smoking mobile application. based on nice guidance and best practice for smoking cessation, the application employs over 30 behaviour change techniques used in nhs stop smoking services. it has been downloaded over 4 million times and has an average user rating of 4.7 out of 5, from over 120,000 ratings. whilst user feedback has been highly positive, there is a need for further objective studies to demonstrate its efficacy. this is a prospective, observational, two arm feasibility study, which aims to evaluate the efficacy, attrition rate and user experience of the smokefree app. inpatients in the acute medical unit and ambulatory emergency care unit at chelsea and westminster hospital who are current smokers will be offered to participate in the study, in addition to all other smoking cessation interventions, which will also be offered to them. care will be taken to ensure that all available options of smoking cessation support are offered in addition to the smokefree application. subjects agreeing to participate will be given access to the application for a period of 12 weeks, with a target quit date no later than week 8 of use of the application. at the end of 12 weeks they will be offered a follow up appointment in a purposely designed clinic, where their co level will be measured, as well as being invited to complete feedback questionnaires on their experience. the primary end point of the study will be the quit rate for a period of minimum of 4 weeks by the completion of the 12 week trial. this will be confirmed with exhaled carbon monoxide testing. secondary endpoints include user experience, engagement with the mobile application and attrition rate.


Eligibility criteria:
inclusion criteria: intervention: * ≥ 18 years * all new patients admitted via the acute medical via aau (or aec) * current smoker and willing to quit * smartphone owner * fluent in english (verbal and written) * able to give informed consent * able and willing to attend a follow up visit in 12 weeks. control: - meet above inclusion criteria except ownership of smartphone. exclusion criteria: * \< 18 years * patient refusal

Keywords: acute assessment unit ambulatory emergency care
anti-cytokine therapy for hemodialysis inflammation

Conditions: End-Stage Renal Disease

Summary: anti-cytokine therapy for hemodialysis inflammation (action) is a phase ii multi-center study to evaluate the safety and tolerability of anakinra, an il-1 receptor antagonist, for patients treated with maintenance hemodialysis.

the action trial will enroll 80 participants being treated with maintenance hemodialysis for end-stage renal disease. participants will be randomized to receive anakinra, 100 mg administered intravenously 3 times per week at the end of the hemodialysis session, or matched placebo. the duration of study drug administration is 24 weeks. there will be an additional 24 weeks of follow-up after study drug administration has been completed.

Eligibility criteria:
inclusion criteria: 1. maintenance hemodialysis therapy 3 times per week for end-stage renal disease 2. ≥6 months since hemodialysis initiation 3. c-reactive protein measured by high sensitivity assay (hscrp) ≥2.0 mg/l at screening and within 10 days prior to randomization 4. most recent single pool kt/v \> or = 1.2 within 30 days prior to first screening visit 5. negative tuberculosis interferon gamma release assay (e.g. quantiferon-tb gold) for tuberculosis unless documented treatment for a) positive ppd, b) positive interferon gamma release assay, or c) tuberculosis. 6. negative human immunodeficiency virus (hiv) antibody test, negative hepatitis c ab test unless viral clearance following direct antiviral therapy is documented, and negative hepatitis b surface antigen positivity. 7. for women of childbearing potential, willingness to use a highly effective method of birth control for up to 4 weeks after the last dose of anakinra. 8. ability to provide informed consent exclusion criteria: 1. current or anticipated use of a hemodialysis central venous catheter 2. acute bacterial infection, including vascular access infection, within 60 days prior to screening unless treated with antibiotics and resolved. any chronic bacterial infection (e.g., osteomyelitis or bronchiectasis) 3. hospitalization within 30 days unless for vascular access procedure 4. cirrhosis 5. malignancy within the past 5 years with exception of basal or squamous cell carcinoma 6. use of an immunosuppressive drug within the past 3 months except low doses of oral corticosteroids (total daily dose ≤10 mg/day of prednisone or equivalent) 7. receipt of live vaccine within the past 3 months. live vaccines include varicella zoster, measles, oral polio, rotavirus, yellow fever, and the nasal spray influenza vaccine 8. absolute neutrophil count (anc) \<2,500 cells/mm3 (2.5 x 109 cells/l) 9. platelet count \<100,000/mm3 (100 x 109/l) 10. known allergy to anakinra 11. anticipated kidney transplantation, change to peritoneal dialysis, or transfer to another dialysis unit within 9 months 12. expected survival less than 9 months 13. pregnancy, anticipated pregnancy, or breastfeeding 14. incarceration 15. receipt of an investigational drug within the past 30 days 16. current or anticipated participation in another intervention study

Keywords: esrd end-stage kidney disease
carbon dioxide（co2）fractional laser plus photodynamic therapy in female patients with vulvar lichen sclerosus

Conditions: Vulva Lichen Sclerosus

Summary: the objective of this study is to evaluate the safety and efficacy of co2 fractional laser combined with photodynamic therapy in female patients with vulvar lichen sclerosus.

this is a randomized, open-labeled, assessor-blind, parallel control study. 134 enrolled patients will be randomized to apply either topical 0.1% corticosteroid mometasone furoate(mmf) ointment or photodynamic therapy. for patients who receive photodynamic therapy, lesions will be symmetrically randomized into two sides. one side will receive co2 fractional laser before photodynamic therapy, while the other side will receive photodynamic therapy only.

Eligibility criteria:
inclusion criteria: 1. age 18-60 (inclusive), female patients; 2. present typical clinical manifestations of of vulvar lichen sclerosus, confirmed by histopathological examination; 3. volunteer to participate in this study and sign an informed consent form. exclusion criteria: 1. severe organic diseases, such as severe heart, lung, liver, kidney insufficiency, coagulation dysfunction, etc.; 2. suffer from autoimmune diseases, such as systemic lupus erythematosus, thyroid disease, etc.; 3. suffer from photoallergic diseases, such as chronic photosensitivity dermatitis, plant solar dermatitis; 4. people with porphyria or porphyria allergy; 5. suffer from psychiatric diseases, such as schizophrenia, etc.; 6. those who are undergoing systemic treatment due to malignant tumor diseases, such as cervical cancer; 7. it is confirmed by laboratory pathogenic screening to have syphilis, hiv, and other sexually transmitted diseases or viral hepatitis; 8. patients with current bacterial or fungal infections in the anus and genitals; 9. women of childbearing age who have pregnancy plans, are pregnant, or are breastfeeding during the observation period of this study; 10. patients who are systematically using glucocorticoids, immunosuppressants, and anticoagulants; 11. use glucocorticoids for topical or local injection and calcineurin inhibitors for topical use within 4 weeks; 12. those who are allergic to 5-aminolevulinic acid or its base, mometasone furoate or its base; 13. other situations that the investigator considers inappropriate to participate in the clinical study.

Keywords: vulva lichen sclerosus female co2 fractional laser photodynamic therapy